Daklinza (daclatasvir)

What type of adverse reactions were reported when taking Daklinza?

UPDATE: Bristol Myers Squibb discontinued Daklinza effective June 2019.

The most common side effects observed when using Daklinza in combination with sofosbuvir were headache and fatigue (in 10% or more of patients).

The FDA has warned that a serious slowing of the heart rate (symptomatic bradycardia) can occur when Daklinza is coadministered with amiodarone and sofosbuvir.

Last Updated: June 2019

When is Daklinza contraindicated? Are there any other warnings one should know regarding Daklinza?

References

FDA Approved Daklinza (Daclatasvir) for the Treatment of Patients with Chronic Hepatitis C Genotype 3. http://news.bms.com/press-release/fda-approves-daklinza-daclatasvir-treatment-patients-chronic-hepatitis-c-genotype-3, Bristol-Myers Squibb Company. Retrieved July 27, 2015.

Financial Help Info for Daklinza (daclatasvir) . http://www.daklinza.bmscustomerconnect.com/support, Bristol-Myers Squibb Company. Retrieved July 27, 2015.

Highlights of Prescribing Information - DAKLINZA. http://packageinserts.bms.com/pi/pi_daklinza.pdf, Bristol-Myers Squibb Company. Retrieved July 27, 2015.

Patient Support Connect. http://www.patientsupportconnect.bmscustomerconnect.com/, Bristol-Myers Squibb Company. Retrieved July 27, 2015.